Tixagevimab/cilgavimab

Tixagevimab/cilgavimab is a combination of two monoclonal antibodies designed for the prevention and treatment of COVID-19. The combination is marketed under the brand name Evusheld by AstraZeneca. It was granted emergency use authorization by the FDA in the United States in December 2021.

Mechanism of Action[edit]

Tixagevimab and cilgavimab are monoclonal antibodies that bind to different, non-overlapping epitopes of the spike protein of SARS-CoV-2, the virus that causes COVID-19. By binding to the spike protein, they prevent the virus from entering human cells, thereby preventing infection.

Clinical Trials[edit]

The effectiveness of tixagevimab/cilgavimab was demonstrated in a Phase 3 clinical trial involving over 5,000 participants. The trial found that the combination reduced the risk of developing symptomatic COVID-19 by 77%.

Side Effects[edit]

Common side effects of tixagevimab/cilgavimab include injection site reactions, headache, and fatigue. Serious side effects are rare but can include allergic reactions.

Authorization[edit]

Tixagevimab/cilgavimab was granted emergency use authorization by the FDA in the United States in December 2021 for the pre-exposure prophylaxis (prevention) of COVID-19 in certain individuals.